ERBB2 and breast cancer: The upper limit of the price range of T-DXd considered cost-effective at a WTP threshold of $100,000/QALY was $35.70/mg for all HER2-low advanced BC patients, $35.27/mg for all HER2+ advanced BC patients and $32.07/mg for all HER2- advanced BC patients.